Reassuring safety data with investigational lipid-modifying agent
David Kallend (The Medicines Company, Parsippany, NJ, USA)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs Dr. Kallend shares data of a phase I trial with ApoA1-Milano-POPC (MDCO216), which was well-tolerated and showed an increase in efflux in patients with recent CAD but who are clinically stable.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.